Jagsonpal Pharmaceuticals Share Price Target 2026 Analyst Forecast Bull and Bear Case

Jagsonpal Pharmaceuticals (NSE: JAGSNPHARM) is a Pharmaceutical Formulations and Branded Generics company trading at Rs 222.71 with a market capitalisation of Rs 945 crore. Analysts have set the Jagsonpal Pharmaceuticals share price target at Rs 265 for 2026, based on FY27 earnings projections and sector re-rating potential. This article covers the complete 2026 price forecast including sector tailwinds, key risks, and bull and bear scenarios.

Click Here – Get Free Investment Predictions

Jagsonpal Pharmaceuticals Share Price Target 2026: Key Takeaways

• Jagsonpal Pharmaceuticals share price target 2026: Rs 265 (20% upside from CMP Rs 222.71)
• Bull case: Rs 325 | Bear case: Rs 180
• Ticker: JAGSNPHARM | Sector: Pharmaceutical Formulations and Branded Generics | MCap: Rs 945 crore
• 52W range: Rs 154 to Rs 365 | PE: 15x
• Key catalyst: Q4 FY26 results and FY27 earnings confirmation in 2026
• Key risk: FY27 earnings miss or FII outflows from Indian equities

Jagsonpal Pharmaceuticals Company Overview

Jagsonpal Pharmaceuticals (NSE: JAGSNPHARM) is a New Delhi-based manufacturer of branded pharmaceutical formulations including cardiovascular, anti-diabetic, and dermatology drugs for hospital and retail prescription segments across India. At CMP Rs 222.71 against a 52 week range of Rs 154 to Rs 365, the stock trades at a meaningful discount to its 52 week high. Market capitalisation is Rs 945 crore with trailing PE of 15x. Compared to peers in branded generics like Alembic Pharmaceuticals and Aristo Pharma, Jagsonpal Pharmaceuticals is positioned as a potential re-rating candidate toward the Rs 265 price objective on FY27 earnings delivery.

Parameter	Value
NSE Ticker	JAGSNPHARM
Sector	Pharmaceutical Formulations and Branded Generics
CMP (2026)	Rs 222.71
52 Week High	Rs 365
52 Week Low	Rs 154
Market Cap	Rs 945 crore
Trailing PE	15x
12-Month Analyst Target	Rs 265
Bull Case Target	Rs 325
Bear Case Target	Rs 180

Why Is the Jagsonpal Pharmaceuticals Share Price Target Set at Rs 265 for 2026

FY27 Earnings Recovery and Revenue Acceleration

The Jagsonpal Pharmaceuticals share price target of Rs 265 rests on analyst projections of 15 to 20 percent PAT growth in FY27. Q4 FY26 results released in 2026 confirming the earnings trajectory are the most direct catalyst for re-rating. The Rs 265 price objective represents the base case with FY27 execution as the key variable.

Structural Sector Tailwinds in Pharmaceutical Formulations and Branded Generics

The Pharmaceutical Formulations and Branded Generics sector is expanding on the back of India’s domestic demand growth, PLI scheme support, and rising corporate investment. Jagsonpal Pharmaceuticals’s position among peers in branded generics like Alembic Pharmaceuticals and Aristo Pharma creates a structural growth runway. Sustained outperformance is one of the key conditions for the Rs 325 bull case to materialise.

RBI Rate Cut Cycle and Lower Cost of Capital

India’s RBI rate cut cycle in 2026 is reducing borrowing costs and stimulating end market demand. Lower interest costs improve Jagsonpal Pharmaceuticals’s EPS trajectory, narrowing the gap between current earnings and the FY27 estimates that underpin the Rs 265 analyst consensus.

Union Budget 2026-27 Capex Push and Policy Support

Budget 2026-27’s Rs 11.21 lakh crore infrastructure capex and PLI scheme continuity create a favourable backdrop for Jagsonpal Pharmaceuticals’s Pharmaceutical Formulations and Branded Generics operations, improving the probability of achieving the Rs 265 price objective through FY27 earnings delivery.

FII Flow Normalisation After the 2026 Tariff Shock

As global macro conditions normalise through 2026, FII flows into quality Indian equities are gradually recovering. At 15x PE, Jagsonpal Pharmaceuticals is positioned as a beneficiary of institutional reallocation, providing a tailwind toward the Rs 325 bull case over the medium term.

Jagsonpal Pharmaceuticals Share Price Targets: Short Term, 12 Month, and Long Term

Short Term Jagsonpal Pharmaceuticals Share Price Target

Near-term support for Jagsonpal Pharmaceuticals is anchored close to the 52 week low of Rs 154. A confirmed Q4 FY26 earnings recovery in 2026 is the trigger for an initial 10 to 15 percent re-rating. Investors can use the 52 week low as an entry reference while awaiting FY27 earnings confirmation.

12-Month Jagsonpal Pharmaceuticals Share Price Target 2026

The 12-month Jagsonpal Pharmaceuticals share price target 2026 is Rs 265, implying approximately 20 percent upside from CMP Rs 222.71. This base case assumes in-line FY27 earnings delivery and partial normalisation of FII flows. Track live on NSE ticker JAGSNPHARM.

Long Term Jagsonpal Pharmaceuticals Share Price Target: FY27 to FY28

The long term Jagsonpal Pharmaceuticals share price target for FY27 to FY28 is Rs 325 in the bull case, requiring full earnings delivery, re-rating among peers in branded generics like Alembic Pharmaceuticals and Aristo Pharma, and sustained institutional buying over a 2 to 3 year horizon.

Bull Case and Bear Case Scenarios for Jagsonpal Pharmaceuticals in 2026

Bull Case Jagsonpal Pharmaceuticals Share Price Target: Rs 325

The bull case Jagsonpal Pharmaceuticals share price target of Rs 325 materialises when FY27 earnings beat analyst estimates, Pharmaceutical Formulations and Branded Generics tailwinds accelerate, and FII flows return strongly to Indian equities. From CMP Rs 222.71, this represents approximately 45 percent potential upside.

Bear Case Jagsonpal Pharmaceuticals Share Price Target: Rs 180

The bear case Jagsonpal Pharmaceuticals share price target of Rs 180 materialises if FY27 earnings disappoint or FII outflows depress the broader market, risking a test of support near the 52 week low of Rs 154.

Scenario	Target	Key Conditions
Bull Case	Rs 325	FY27 beat, sector re-rating, FII inflows
Base Case (Analyst Target)	Rs 265	In-line FY27 delivery, partial FII recovery
Bear Case	Rs 180	FY27 miss, guidance cut, FII outflows persist

Key Risks That Could Derail the Jagsonpal Pharmaceuticals 2026 Price Objective

Global Macro and US Tariff Headwinds

Prolonged tariff tensions and global demand slowdown remain prominent macro risks to the Jagsonpal Pharmaceuticals share price target of Rs 265, with FII outflows being the direct transmission mechanism to Indian equity valuations.

FY27 Earnings Miss and Guidance Risk

An FY27 earnings miss or downward guidance revision would compress valuation multiples. This is the most direct company-specific risk to the Rs 265 analyst price objective. Investors must monitor quarterly results and management commentary closely.

Competitive Intensity Among Pharmaceutical Formulations and Branded Generics Peers

Intensifying competition from peers in branded generics like Alembic Pharmaceuticals and Aristo Pharma could compress Jagsonpal Pharmaceuticals’s market share and pricing power. This structural risk must be weighed when assessing the defensibility of the earnings trajectory underpinning the Rs 265 analyst target for 2026.

Liquidity Risk and FII Selling Pressure

Sustained FII outflows from Indian equities can delay the re-rating process regardless of company-level improvement. Investors should maintain position sizing discipline and stop losses to protect capital.

How to Invest in Jagsonpal Pharmaceuticals

Check the Univest Screener for live data

Before considering any investment based on the Jagsonpal Pharmaceuticals share price target of Rs 265, review Q4 FY26 results and FY27 guidance released in 2026. Focus on revenue growth, margin trends, and management commentary on Pharmaceutical Formulations and Branded Generics sector demand.

Open a Demat account with a SEBI registered stockbroker to trade Jagsonpal Pharmaceuticals (NSE: JAGSNPHARM) with regulatory protection. Study the competitive landscape among peers in branded generics like Alembic Pharmaceuticals and Aristo Pharma before executing any position.

Plan your entry using the 52 week low of Rs 154 as a key support reference. A confirmed FY27 earnings uptick validates the entry case for the Rs 265 price objective. Always set a stop loss below the 52 week low.

Restrict any single stock to 3 to 5 percent of your total equity portfolio. Always consult a SEBI registered financial advisor before investing. SEBI Registration No. INH000013776.

Download the Univest iOS App or the Univest Android App to track Jagsonpal Pharmaceuticals’s live share price and receive daily stock recommendations.

FAQs on Jagsonpal Pharmaceuticals Share Price Target 2026

What is the Jagsonpal Pharmaceuticals share price target for 2026?

Ans. The Jagsonpal Pharmaceuticals share price target 2026 is Rs 265, implying approximately 20 percent upside from CMP Rs 222.71. Bull case is Rs 325, bear case is Rs 180.

What was the Jagsonpal Pharmaceuticals share price target for 2025?

Ans. The 2025 price objective for Jagsonpal Pharmaceuticals was based on FY26 earnings projections. The current 2026 analyst consensus is Rs 265, reflecting FY27 growth potential from CMP Rs 222.71.

Is Jagsonpal Pharmaceuticals a good investment at Rs 222.71?

Ans. At Rs 222.71, Jagsonpal Pharmaceuticals offers potential upside toward Rs 265 if FY27 earnings recover. Whether this represents a good entry depends on individual risk tolerance. Consult a SEBI registered financial advisor before investing.

What are the key risks to the Jagsonpal Pharmaceuticals share price target 2026?

Ans. Key risks to the Jagsonpal Pharmaceuticals share price target of Rs 265 include FY27 earnings miss, global tariff headwinds, FII outflows, and competitive pressure in Pharmaceutical Formulations and Branded Generics. Monitoring quarterly results is essential.

What is the 52 week high and low of Jagsonpal Pharmaceuticals?

Ans. The 52 week high of Jagsonpal Pharmaceuticals is Rs 365 and the 52 week low is Rs 154. At CMP Rs 222.71, the stock offers potential upside toward the Rs 265 price objective.

What are the main growth catalysts for Jagsonpal Pharmaceuticals in 2026?

Ans. Key catalysts include FY27 PAT recovery, Pharmaceutical Formulations and Branded Generics tailwinds, RBI rate cuts in 2026, Budget 2026-27 policy support, and normalisation of FII flows into Indian equities.

How does Jagsonpal Pharmaceuticals compare to its peers?

Ans. Jagsonpal Pharmaceuticals operates in Pharmaceutical Formulations and Branded Generics alongside peers in branded generics like Alembic Pharmaceuticals and Aristo Pharma. At CMP Rs 222.71 with MCap Rs 945 crore, it is a potential re-rating candidate toward the Jagsonpal Pharmaceuticals share price target of Rs 265 on FY27 delivery.

What is the Jagsonpal Pharmaceuticals share price target for 2027?

Ans. The long-term Jagsonpal Pharmaceuticals share price target for FY27 to FY28 is Rs 325 in the bull case, assuming earnings growth, sector re-rating, and FII inflows. Consult a SEBI registered financial advisor for personalised guidance.